Despite a dip in M&A value and volume, PwC predicts deal activity to remain strong with an uptick in IPOs
The last 12 months have seen some of the biggest M&A deals in recent years — think Pfizer’s $43 billion acquisition of Seagen and Merck’s nearly …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
